Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50

Benzinga Newsdesk www.benzinga.com Negative 94.6%

Neg 94.6% Neu 0% Pos 0%

Noble Capital Markets analyst Robert LeBoyer maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Outperform and lowers the price target from $60 to $50.